Author:
Ivanyi Philipp,Fröhlich Tabea,Grünwald Viktor,Zschäbitz Stefanie,Bedke Jens,Doehn Christian
Publisher
Deutscher Arzte-Verlag GmbH
Reference76 articles.
1. Zentrum für Krebsregisterdaten, Robert Koch-Institut. 2023. www.krebsdaten.de/Krebs/DE/Content/Krebsarten/Nierenkrebs/nierenkrebs_node.html (last accessed on 11 July 2024).
2. Escudier B, Porta C, Schmidinger M, et al.: Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2019; 30: 706–20.
3. Moch H, Amin MB, Berney DM, et al.: The 2022 World Health Organization classification of tumours of the urinary system and male genital organs—part A: renal, penile, and testicular tumours. Eur Urol 2022; 82: 458–68.
4. Lee CH, Voss MH, Carlo MI, et al.: Phase II trial of cabozantinib plus nivolumab in patients with non-clear-cell renal cell carcinoma and genomic correlates. J Clin Oncol 2022; 40: 2333–41.
5. Ljungberg B, Albiges L, Bedke J, et al.: EAU guidelines on renal cell carcinoma. European Association of Urology. 2023; 1–100. https://uroweb.org/guidelines/renal-cell-carcinoma (last accessed on 11 July 2024).